NeuroSense Investor Relations

NASDAQNRSN

Investor Relations

About Us

Pipeline

Media

Investor RelationsClick here to open mobile navigation

Recent News

Investor Alerts

Dec 4, 2024

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007),...

Dec 2, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry...

Nov 21, 2024

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce...

Latest Events

No events to display

Investor Presentation

Download PDF

Board Diversity Matrix

Download PDF

Investor Relations

Home

Research

About

Publications